Medical Equipment & Devices

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Following a weak FY25, and weak FY26 guidance, Cochlear’s outlook rests on the success of its new Nexa implant and other products. Is the market too confident?

Aug 19 2025

Michael Gable of Fairmont Equities reports buying the dip remains a valid strategy for ResMed shares above new technical support of $40

Jul 29 2025


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
4DX 4DMEDICAL LIMITED $0.77 $0.80 $0.23

$0.73

CAT CATAPULT SPORTS LIMITED $6.07 $6.93 $1.95

$6.333

COH COCHLEAR LIMITED $300.18 $323.00 $246.14 43.3

$311.74

CU6 COCHLEAR LIMITED $2.96 $8.98 $1.43

$7.20

CVB CURVEBEAM AI LIMITED $0.12 $0.20 $0.06

$0.18

CYC CYCLOPHARM LIMITED $1.07 $xx.xx $xx.xx xx.x xx.xx
EBR EBR SYSTEMS INC $1.25 $xx.xx $xx.xx xx.x xx.xx
EMV EBR SYSTEMS INC $1.97 $xx.xx $xx.xx xx.x xx.xx
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED $32.90 $xx.xx $xx.xx xx.x xx.xx
IME IMEXHS LIMITED $0.22 $xx.xx $xx.xx xx.x xx.xx
IMR IMRICOR MEDICAL SYSTEMS INC $1.40 $xx.xx $xx.xx xx.x xx.xx
IPD IMPEDIMED LIMITED $0.04 $xx.xx $xx.xx xx.x xx.xx
MX1 MICRO-X LIMITED $0.08 $xx.xx $xx.xx xx.x xx.xx
NAN NANOSONICS LIMITED $4.29 $xx.xx $xx.xx xx.x xx.xx
ONE ONEVIEW HEALTHCARE PLC $0.23 $xx.xx $xx.xx xx.x xx.xx
PGC PARAGON CARE LIMITED $0.33 $xx.xx $xx.xx xx.x xx.xx
PME PARAGON CARE LIMITED $296.58 $xx.xx $xx.xx xx.x xx.xx
RMD RESMED INC $41.79 $xx.xx $xx.xx xx.x xx.xx
SOM SOMNOMED LIMITED $0.80 $xx.xx $xx.xx xx.x xx.xx
TRJ SOMNOMED LIMITED $0.92 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025

Pro Medicus shares surge on major contract wins and growing AI momentum, reinforcing its position as a high-margin healthcare tech leader against a background of eternal valuation debate


Cochlear Downgrades Ahead Of New Launches

Jun 19 2025

A decline in Services revenue had led to another profit downgrade from Cochlear, but brokers look ahead to new product launches


Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025

A consensus-beating FY25 result from Fisher & Paykel Healthcare was undermined by disappointing FY26 guidance, with tariffs partly to blame


ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025

ResMed’s largely in-line third quarter results showcased a rising gross margin, while management also moved to ease market concerns regarding tariffs


Trend Remains Up For Catapult International

Feb 18 2025

Michael Gable of Fairmont Equities sees an ongoing uptrend for shares in Catapult Group International


ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025

Addressing challenges and opportunities in meeting the UN Sustainable Development Goals and what ESG characteristics underpin share prices


ResMed Shakes Off GLP-1 Scare

Feb 04 2025

The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry


ResMed: Another Positive Quarterly Surprise?

Jan 30 2025

Tomorrow’s release is expected to reveal another strong quarter from ResMed


The Trend Remains Pro Medicus’ Friend

Jan 16 2025

The Chartist reports shares in Pro Medicus are having a breather, with the uptrend likely to continue


Diagnostic Imaging Radiates Opportunity

Dec 18 2024

Pending MRI deregulation is behind the now approved merger of Integral Diagnostics and Capitol Health, and analysts see significant opportunity